|Expense ratio (net)||N/A|
|Last cap gain||N/A|
|Morningstar risk rating||N/A|
|Beta (3Y monthly)||N/A|
|5y average return||N/A|
|Average for category||N/A|
Pfizer Inc. today announced the United States Food and Drug Administration has approved RUXIENCE™ , a biosimilar to Rituxan® ,1 f
LONDON--(BUSINESSWIRE)-- ViiV Healthcare , the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 96 results from ...
These are the clinical trial readouts, FDA decisions, and blockbuster-drug launches that will set the tone for the entire industry.
The drug companies provide rebates to PBMs in exchange for distributing their products.
T-Mobile, Tesla, Marriott, GlaxoSmithKline, Pfizer and Caliva are the companies to watch.
LONDON--(BUSINESSWIRE)-- ViiV Healthcare , the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from ...
Sangamo Therapeutics reported positive data on its gene therapy for hemophilia, and CannTrust Holdings received a noncompliance report from Canadian authorities.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE) today announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. The data showed that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) activity levels. The first two patients treated at the 3e13 vg/kg dose rapidly achieved normal levels of FVIII activity as measured using a chromogenic assay, with no reported bleeding events, and the response continues to be durable for as long as 24 weeks, the extent of follow-up. The two patients more recently treated at the 3e13 vg/kg dose level are demonstrating FVIII activity kinetics that appear consistent with the first two patients treated in this dose cohort at similar early time points.
After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.
Deborah Waterhouse, CEO, ViiV Healthcare, said: “For many years, the standard of care for treatment-naïve people living with HIV in Europe has been a three-drug regimen. The data from our dolutegravir-based two-drug regimen development programme challenges this, and with the authorisation of Dovato, people living with HIV can for the first time start treatment on a once-daily, single-pill, two-drug regimen with the knowledge that efficacy is non-inferior to a three-drug regimen whilst containing fewer antiretrovirals. With around 25,000 new HIV diagnoses in Europe* every year2, and the fact that today HIV is considered a chronic condition which requires people living with HIV (PLHIV) to remain on antiretroviral (ARV) treatment for life, it is ever more important to provide innovative treatment options.
"I don't think it is that feasible, quite frankly," says Dr. Scott Gottlieb. "It would crowd out competition in private insurance."
"This kind of revolving door influence-peddling smacks of corruption, and makes the American people rightly cynical and distrustful about whether high-level Trump administration officials are working for them, or for their future corporate employers," Warren said in a July 1 letter to Gottlieb.
Pfizer last week announced Gottlieb would join its board of directors — a job that paid a minimum of $335,000 in stock and cash in 2018.
Pfizer Inc. (PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46. TA-46 is an investigational medicine for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism.
Shares of Pfizer Inc. ticked up 1.2% in premarket trade Monday after the drugmaker said a Phase 4 study showed that an eczema treatment was well-tolerated in babies between 3 months and two years of age when used over a period of four weeks. The treatment, a crisaborole ointment that is steroid-free, is currently approved in the U.S. to treat eczema in children two years of age and older. The company said a detailed analysis of the study would be presented later at a scientific meeting. Shares of Pfizer have gained 19.4% in the past 12 months, while the S&P 500 has gained 8.2%.